Put the receptor diagrams for MariTide and tirzepatide beside each other and one arrow appears to point the wrong way. Both activate the GLP-1 receptor, but tirzepatide activates the GIP receptor while MariTide blocks it.[1][2] How can researchers pursue both approaches for weight management? Understanding receptor activity and explaining clinical weight loss require different evidence.
What activation and blockade mean
GIP stands for glucose-dependent insulinotropic polypeptide. It is an incretin, a gut hormone released after eating that helps coordinate insulin secretion. Its actions depend on context: GIP can stimulate insulin when glucose is high and glucagon, another glucose-regulating hormone, when glucose is low. GIP receptors also occur outside the pancreas, including fat tissue and parts of the nervous system.[2]
An agonist activates a receptor; an antagonist blocks its activation. These terms do not guarantee a direction of whole-body weight change. Calling GIP simply a “fat-storage hormone” overlooks its different contexts. The discovery literature itself discusses apparently conflicting findings about GIP and body weight.[2]
Two different molecular designs
Tirzepatide's discovery identifier was LY3298176. The 2018 paper describes a 39-amino-acid peptide modified with a fatty-acid component that enables binding to albumin, a blood protein, and prolongs exposure. Cell experiments demonstrated activation of both GIP and GLP-1 receptors; experiments in mice supported glucose-regulating activity through either receptor.[2]
MariTide, also called maridebart cafraglutide or AMG 133, is a long-acting peptide–antibody conjugate: peptide and antibody components are joined in one molecular design. Its combined activities are GLP-1 receptor agonism and GIP receptor antagonism.[1][3] It therefore differs from tirzepatide in molecular construction as well as the direction of GIP receptor activity.
| Feature | Tirzepatide | MariTide |
|---|---|---|
| Molecular format | Modified peptide.[2] | Peptide–antibody conjugate.[1] |
| GLP-1 receptor activity | Agonist.[2] | Agonist.[1] |
| GIP receptor activity | Agonist.[2] | Antagonist.[1] |
| Clinical evidence examined here | Early discovery and Phase 1 report.[2] | Placebo-controlled Phase 2 report.[1] |
| What this comparison establishes | Different receptor strategy. | Different receptor strategy, not superiority. |
Receptor count is not a potency score. A shared target list does not establish equivalent activity, clinical benefit or interchangeability.[1][2]
What the MariTide Phase 2 trial measured
The 2025 report describes a double-blind, randomized, placebo-controlled trial involving 592 participants. There were 465 participants in an obesity cohort and 127 in a cohort with obesity and type 2 diabetes. Investigators studied injected MariTide across multiple treatment groups, with percentage weight change at 52 weeks as the primary endpoint.[1]
Using the treatment-policy estimand, an intention-to-treat approach, mean weight change ranged from −12.3% to −16.2% across MariTide groups in the obesity cohort, versus −2.5% for placebo. In the diabetes cohort, the range was −8.4% to −12.3%, versus −1.7% for placebo.[1] These are averages across tested regimens, not promised individual outcomes.
In the diabetes cohort, glycated hemoglobin, a measure of longer-term glucose exposure, fell by 1.2–1.6 percentage points with MariTide, compared with a 0.1-point rise with placebo.[1] Weight and glucose outcomes answer distinct questions.
The comparator was placebo. This trial cannot determine whether MariTide matches or exceeds tirzepatide, and its reported weight changes do not establish cardiovascular benefit.[1] The early tirzepatide paper also studied different populations over much shorter clinical periods, making a numerical ranking especially misleading.[2]
Why the biological explanation remains unsettled
The tirzepatide discovery paper reviews an instructive contradiction: mice lacking the GIP receptor and mice engineered to overproduce GIP had both shown resistance to obesity. It also reports that a long-acting GIP agonist alone did not reduce weight in its obese-mouse experiments, while combined GIP/GLP-1 agonism produced greater weight loss than the tested GLP-1 comparator.[2]
The authors proposed synergistic signaling, potentially through nervous-system pathways. GIP's involvement in fat-tissue metabolism also helps explain interest in blockade.[2] These observations motivate hypotheses; genetically modified mice, drug-treated mice and human participants are different experimental settings.
The clinical contribution of each component remains a separate problem. The early tirzepatide trial could not distinguish the contributions of GIP and GLP-1.[2] Similarly, comparing the complete MariTide molecule with placebo tests its combined effect, not the isolated contribution of blocking GIP.[1] Positive clinical results can support further development while leaving the precise mechanism of weight reduction unresolved.
What Amgen reported in August 2026
Amgen's August 2026 update described MARITIME-1 and MARITIME-2 Phase 3 weight-management studies as ongoing, with cardiovascular, heart-failure and sleep-apnea studies enrolling. It also described a study involving participants previously receiving tirzepatide or semaglutide, long-term extensions and an enrolling Phase 2b liver-fat study.[3]
These are dated sponsor statements. Cardiovascular trial enrollment does not demonstrate fewer cardiovascular events, and a treatment-transition study supplies no established switching guidance. The update reports plans and trial status, not Phase 3 results, interchangeability or a regulatory approval.[3]
Safety and the boundary around research materials
Gastrointestinal adverse events were common in the MariTide trial, although less frequent with the tested escalation approaches and lower starting amounts. Investigators reported no unexpected safety signals.[1] That phrase does not mean no adverse events, nor can this study exclude every rare or delayed harm. The early tirzepatide study likewise reported gastrointestinal effects and emphasized its small sample and short duration.[2]
Laboratory research materials should not be consumed or self-administered. Compound identity or analytical purity does not establish appropriate clinical formulation, sterility or human benefit. FDA warns that unapproved GLP-1 products have not undergone its premarket review and describes harmful dosing errors and products falsely marketed to consumers as research materials.[4] Research characterization does not establish human-use suitability, even when a reagent has been tested.
Source note: This article uses the original MariTide Phase 2 abstract, the full 2018 tirzepatide discovery paper, relevant sections of Amgen’s dated August 2026 update and FDA safety information retrieved October 23, 2026. The MariTide full paper was not accessed. FDA information provides general unapproved-product context, not a MariTide-specific warning. This is editorial source review, not medical review or a Chudik experiment.